This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

MR, OPK, CTRX And DGX, 4 Health Services Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 71 points (0.4%) at 16,428 as of Thursday, Dec. 26, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,679 issues advancing vs. 1,241 declining with 183 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.3%. A company within the industry that increased today was Express Scripts ( ESRX), up 0.9%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Mindray Medical International Limited ADR r ( MR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mindray Medical International Limited ADR r is down $1.13 (-3.0%) to $36.30 on average volume. Thus far, 428,353 shares of Mindray Medical International Limited ADR r exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $36.30-$37.75 after having opened the day at $37.75 as compared to the previous trading day's close of $37.43.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International Limited ADR r has a market cap of $4.5 billion and is part of the health care sector. Shares are up 14.5% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Mindray Medical International Limited ADR r a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mindray Medical International Limited ADR r as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Mindray Medical International Limited ADR r Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs